Lyon (France) – December 2017. NEURONAX, a clinical-stage biopharmaceutical company dedicated to develop innovative therapies for patients with traumatic or severe neurological disorders with high unmet medical needs, announced to strengthen its Leadership Team with the appointments of Sébastien MARIE as Director of Clinical Operations and Dr. Manuel BLANC, Ph.D, as Head of Preclinical Operations & Strategic Alliances.
« I am very proud to welcome Sébastien and Manuel who will enrich the company by their professional skills, their dynamism and their efficacy. » commented Yann GODFRIN, Chief Executive Officer of NEURONAX.
Sébastien MARIE said “I am very pleased to join Neuronax at this position, first to manage a clinical study in spinal cord injury, a challenging pathology. This is the beginning of a great and thrilling adventure with the team, as NX210 is also very promising in other indications like neurodegenerative diseases.”
Dr. BLANC added “I am very proud to join Neuronax and its team of brilliant scientists. The unique properties of NEURONAX’s lead product NX210 and other drug candidates make them promising potential therapeutic solutions for patients with traumatic or degenerative disorders of the central nervous system. I look forward to leading the research & development of these promising therapies and the strategic initiatives necessary to accelerate the growth of the company”
Sébastien MARIE brings 15+ years of experience in clinical trial management. Prior to joining NEURONAX, he served as Clinical Project Manager for a mid-size CRO, managing various full-service national and international projects with biotech and big/mid-size pharma companies, from regulatory submissions to clinical study report writing. He recently participated in the development of drugs in rare diseases, managing several partners in Europe and in the US. Sébastien holds a Master Degree in biology, is specialized in clinical research and certified in international project management.
Manuel BLANC brings 10+ years of experience in Preclinical Project Management, Strategy & Business Development in the biotech – pharma – healthcare industry. Prior to joining NEURONAX, he served as Business Development & Licensing Project Leader for ERYTECH Pharma, directing projects to support corporate strategy, clinical and preclinical R&D and Intellectual Property. Prior to joining Erytech Pharma, Dr. BLANC served as Corporate Strategic Intelligence Manager at SANOFI, in the Strategy Department, managing critical projects to support Business Development and R&D. With dual-skills in Science & Business, Dr. BLANC holds a PhD in Life Sciences (U.K.) and a Master of Business in “Biotechnology & Pharmaceutical Management” (France).
Founded in 2003, NEURONAX is a biopharmaceutical and clinical-stage company developing innovative therapies for patients with traumatic or severe neurological disorders with high unmet medical needs. NEURONAX’s ambition is to improve the recovery of the functionality and the quality of life of patients.
NEURONAX’s products are First-in-Class drug candidates covering a large set of indications in neural-repair treatment (traumatic and degenerative diseases) with high unmet medical needs. NX210, NEURONAX’s lead product, is an injectable drug for which the company obtained the authorization to enter in clinical trial (phase I) for patients with Spinal Cord Injury. In addition, NX210 and its analogs demonstrated promising preliminary results in neurodegenerative diseases.